Phase 1 Study Finds T20K, Plant Protein-derived Compound for MS, Safe and Tolerable, Cyxone Says

Phase 1 Study Finds T20K, Plant Protein-derived Compound for MS, Safe and Tolerable, Cyxone Says

Publication date: Aug 06, 2019

A Phase 1 clinical trial found T20K, Cyxone’s investigational plant protein-derived treatment for multiple sclerosis (MS), to be safe and well-tolerated in healthy men, and raising the possibility that it might work at low doses, the company announced. Preclinical studies showed that T20K works to lower the production of pro-inflammatory cytokines – signaling molecules that mediate inflammation – such as IL-2, and can effectively ease disease symptoms in animal models of MS. Results also noted that T20K, administered orally to the animals, had low toxicity and favorable pharmacokinetics (absorption, distribution, metabolism, and excretion in the body), suggesting that it may be a safe and effective therapy at low doses and with a low frequency of administration that might be every two weeks or monthly. Since this initial and very low dose of T20K showed a favorable pharmacokinetics profile, researchers did not need to study a planned second and higher dose, the company said in its release.

Concepts Keywords
Blood Pharmacokinetics
CEO Zaurategrast
Clinical Trial Pyrimidines
CRO Organofluorides
Cytokines Bioavailability
Double Blind Toxicology
Excretion Dose
Headache Articles
Inflammation Chemical compounds
Intravenously Life sciences
Metabolism Mild transient headache
Netherlands MS
Pharmacokinetics Pro inflammatory cytokines
Prophylactic
Protein
Species
Tolerability
Toxicity

Semantics

Type Source Name
disease MESH sclerosis
disease MESH men
gene UNIPROT PTPN5
disease MESH inflammation
gene UNIPROT IL2
pathway BSID Metabolism
disease MESH diagnosis
disease MESH disease progression
pathway BSID Release
disease MESH uncertainty
gene UNIPROT RXFP2

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *